June 26, 2010 – Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor (MetAP2), for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models. These findings are significant as they show for the first time the long-term weight- and glucose-lowering effects of MetAP2 inhibitors in rodent and non-rodent models of obesity, supporting their potential for treatment of human obesity and its related metabolic disorders. MetAP2 inhibitors work by reestablishing balance to the ways the body processes fat, leading to substantial loss of body weight and improved glucose tolerance... [PDF] Zafgen's Press Release -
Showing posts with label Zafgen. Show all posts
Showing posts with label Zafgen. Show all posts
Thursday, July 1, 2010
Zafgen : Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting
June 26, 2010 – Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor (MetAP2), for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models. These findings are significant as they show for the first time the long-term weight- and glucose-lowering effects of MetAP2 inhibitors in rodent and non-rodent models of obesity, supporting their potential for treatment of human obesity and its related metabolic disorders. MetAP2 inhibitors work by reestablishing balance to the ways the body processes fat, leading to substantial loss of body weight and improved glucose tolerance... [PDF] Zafgen's Press Release -
Thursday, August 28, 2008
Anthill Technologies : Agreement with Zafgen
August 25, 2008 - Anthill Technologies, Inc. announced that it has entered into an agreement with Zafgen, Inc. to apply its high-speed chemistry technologies and capabilities to Zafgen’s obesity program. Zafgen, Inc. is a Boston-based biopharmaceutical company which develops obesity therapy based on the vascular targeting of adipose tissue.Under the agreement, Anthill will use its ACOS™ high-speed synthesis and on-demand purification capabilities to assist Zafgen in the development of lead compounds for its obesity therapy programs...
Anthill Technologies' Press Release -
Subscribe to:
Posts (Atom)
